Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer
Published 04 July 2022 – ESMO OPEN (2022)
Authors: E. Castro, A. Wong, K. Fizazi, M.L.K. Chua, Y. Zhu, H. Malhotra, Y. Miura, J.L. Lee, F.L.T. Chong, Y.-S. Pu, C.-C. Yen, M. Saad, H.J. Lee, H. Kitamura, K. Prabhash, Q. Zou, G. Curigliano, E. Poon, S.P. Choo, S. Peters, E. Lim, T. Yoshino & G. Pentheroudakis
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of prostate cancer was published in 2020. It was therefore decided, by both the ESMO and the Singapore Society of Oncology (SSO), to convene a special, virtual guidelines meeting in November 2021 to adapt the ESMO 2020 guidelines to take into account the differences associated with the treatment of prostate cancer in Asia.
These guidelines represent the consensus opinions reached by experts in the treatment of patients with prostate cancer representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with prostate cancer across the different regions of Asia.